NCT01022853View on ClinicalTrials.gov

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Neoplasms
Interventions
DRUG

BI 6727

intravenous each 21 days

DRUG

BIBF 1120

oral continuously

Trial Locations (2)

Unknown

1230.7.39002 Boehringer Ingelheim Investigational Site, Ancona

1230.7.39001 Boehringer Ingelheim Investigational Site, Milan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01022853 - Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors | Biotech Hunter | Biotech Hunter